


## Afatinib (BIBW2992) Datasheet

### Technical Data

Molecular Weight (MW)	485.94	Solubility (25°C)	DMSO 97 mg/mL
Formula	C <sub>24</sub> H <sub>25</sub> ClFN <sub>5</sub> O <sub>3</sub>		Water <1 mg/mL
CAS No.	439081-18-2, 936631-70-8 (Maleic acid), 1254955-21-9 (XHCl)		Ethanol 15 mg/mL
Synonyms	Tomtovok	Storage	2 years -20°C Powder
			2 weeks 4°C in DMSO
			6 months -80°C in DMSO

Afatinib (BIBW2992) Chemical Structure



### Biological Activity

Description	BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly inhibits EGFR/HER2 including EGFR <sup>wt</sup> , EGFR <sup>L858R</sup> , EGFR <sup>L858R/T790M</sup> and HER2 with IC <sub>50</sub> of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.				
Targets	EGFR <sup>wt</sup>	EGFR <sup>L858R</sup>	EGFR <sup>L858R/T790M</sup>	HER2	
IC <sub>50</sub>	0.5 nM	0.4 nM	10 nM	14 nM <sup>[1]</sup>	
In vitro	BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. <sup>[1]</sup>				
In vivo	Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. <sup>[1]</sup>				
Clinical Trials	A Phase II clinical trial of BIBW2992 for the treatment of cancer has been terminated.				
Features					

### Protocol (Only for Reference)

#### Kinase Assay: <sup>[1]</sup>

In vitro kinase activity assays	The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
---------------------------------	---

#### Cell Assay: <sup>[1]</sup>

Cell Lines	NSCLC cells
Concentrations	0-10 μM
Incubation Time	1 hour
Methods	1 × 10 <sup>4</sup> NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPES buffer per well and shaken at room temperature for 1 hour. In all 2 × 10 <sup>4</sup> cells per well is used for the HER2 phosphorylation assay. Streptavidin pre-coated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5 (Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction was measured at 450 nm.

#### Animal Study: <sup>[1]</sup>

Animal Models	Athymic NMRI-nu/nu female mice
Formulation	In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Doses	20 mg/kg
Administration	Oral administration

### Return Policy

Selleck Chemicals wishes you the best possible online shopping experience with our 365 day unconditional Return Policy. If you are not satisfied with your purchase, either for protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please see the following instructions when you return products.

1. All requests for returns should be communicated to Selleck Chemicals prior to shipping. Any items returned to Selleck Chemicals should be in the original packaging and in the same condition as originally purchased.
2. When returning purchased goods, please inform us of the purchase order number or package tracking number.
3. Return shipping is absolutely FREE.
4. This offer is only valid for products purchased directly from Selleck and its authorized distributors.
5. Once your return request is received and approved, your refund will be processed or automatically applied to your credit card within 7 days. Please note that depending on your credit card company, it may take additional 2-10 business days for us to post the refund to your account.

### Toll Free:

(877) 796-6397

-- USA and Canada only --

### Fax:

+1-713-796-9816

### Orders:

+1-832-582-8158

sales@selleckchem.com

### Tech Support:

tech@selleckchem.com  
(chemistry support)

techbio@selleckchem.com  
(biology support)


### Website:

www.selleckchem.com

References


[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Customer Reviews



S101102Z0220110601

Data from [Int J Proteomics , 2011.June, 2011:Article ID 215496]  
**Afatinib (BIBW2992)** purchased from **Selleck**  
 Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ~80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.



S101102Y0320110601

Data from [Int J Proteomics , 2011.June, 2011:Article ID 215496]  
**Afatinib (BIBW2992)** purchased from **Selleck**  
 Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

**PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE**

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality, but save your shipping charges by using the most economical storage conditions for an overnight shipment. Upon receipt of the product, follow the storage recommendations on the product datasheet.